Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Rawlins

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Journal of Medicinal Chemistry|March 19, 2004
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|September 3, 2015
Correction to N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor AgentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|May 10, 2017
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
Journal of Medicinal Chemistry|August 23, 2002
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, S David Kimball, Raj N Misra, et al.
Journal of Medicinal Chemistry|July 18, 2017
Correction to Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
ACS Chemical Biology|October 19, 2018
Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6William McCoull, Tony Cheung, Erica Anderson, et al.
ACS Medicinal Chemistry Letters|November 21, 2017
Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors"Jeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
Nature Communications|December 19, 2018
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemiaAdriana E Tron, Matthew A Belmonte, Ammar Adam, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 InhibitorsJeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
Journal of Medicinal Chemistry|September 3, 2021
Optimization of an Imidazo[1,2-<i>a</i>]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with <i>In Vivo</i> EfficacyWilliam McCoull, Scott Boyd, Martin R Brown, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Journal of Medicinal Chemistry|March 19, 2004
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|September 3, 2015
Correction to N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor AgentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|May 10, 2017
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
Journal of Medicinal Chemistry|August 23, 2002
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, S David Kimball, Raj N Misra, et al.
Journal of Medicinal Chemistry|July 18, 2017
Correction to Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic InhibitorsWilliam McCoull, Roman D Abrams, Erica Anderson, et al.
ACS Chemical Biology|October 19, 2018
Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6William McCoull, Tony Cheung, Erica Anderson, et al.
ACS Medicinal Chemistry Letters|November 21, 2017
Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors"Jeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
Nature Communications|December 19, 2018
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemiaAdriana E Tron, Matthew A Belmonte, Ammar Adam, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 InhibitorsJeffrey W Johannes, Stephanie Bates, Carl Beigie, et al.
Journal of Medicinal Chemistry|September 3, 2021
Optimization of an Imidazo[1,2-<i>a</i>]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with <i>In Vivo</i> EfficacyWilliam McCoull, Scott Boyd, Martin R Brown, et al.
Pageof 5